Fig. 1From: NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesotheliomaStudy design of the NIPU trial. Patients with MPM and progression after first line platinum-based chemotherapy are randomised (1:1) to ipilimumab and nivolumab alone or in combination with UV1 vaccine.Back to article page